Khaled Musallam/LinkedIn
Aug 13, 2026, 11:05
Khaled Musallam: The Evolving Landscape of β-Thalassemia: Clinical Trial Advances Since 2021
Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in American Journal of Hematology, adding:
“Pleased to share our latest ‘2026 Update on Clinical Trials in β-Thalassemia,’ published today in the American Journal of Hematology.
It is incredibly fulfilling to reflect on how much the field has advanced since our last update in 2021 with new approvals and an expanding pipeline continuing to reshape the treatment landscape for β-thalassemia.”
Title: 2026 Update on Clinical Trials in β-Thalassemia
Authors: Khaled M. Musallam, Franco Locatelli, Mattia Algeri, Maria Domenica Cappellini, Ali T. Taher
Stay updated with Hemostasis Today.
-
Sep 29, 2026, 12:02Hajra Malik: Bridging Language Gaps in Hematology With AI
-
Sep 29, 2026, 11:57Joan Montaner: Can Blood Test Identify Intracerebral Hemorrhage Within Minutes?
-
Sep 29, 2026, 11:43From Years Without Answers to Life With Hemophilia Care – WFH
-
Sep 29, 2026, 11:32Sara Al Dallal: Transforming Hemophilia Care Across the Gulf
-
Sep 29, 2026, 11:21Richard Davis: Rapid Rescue in Massive Pulmonary Embolism
-
Sep 29, 2026, 11:14Nissan Brown: Every Step Counts for the Hemophilia Community
-
Sep 29, 2026, 11:03Zain Khalpey: SINGLE AF Adds New Evidence to the Anticoagulation Debate
-
Sep 29, 2026, 10:54How Does Haemophilia Affect Motor Development in Infants? – EAHAD
-
Sep 29, 2026, 10:49Alison Davey: The Vital Role of Community Support in Bleeding Disorders